Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORTUNE trial of E7090 in advanced or recurrent solid tumors with FGFR alterations
jRCT2031210043Phase 2Recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tasurgratinib in Nonhematologic neoplasms, sponsored by Eisai Co., Ltd. Primary endpoint: Objective response rate. Started Jul 2021; status: recruiting.
02
Drugs
tasurgratinib
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210043.